Streetbeat News

Regulatory

JAGX

Jaguar Health has announced that it has been granted a new patent in Japan. The patent is for the company's proprietary drug, Mytesi, which is used for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

Portfolio Pulse from Bill Haddad

September 13, 2023 | 12:33 pm

IINN

Inspira has announced the 510(k) FDA submission of INSPIRA ART100, with management estimating FDA clearance within approximately 6 months.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2023 | 12:32 pm

SPY

The USA Core CPI (YoY) for August was reported at 4.3%, matching the estimated figure but lower than the prior figure of 4.7%.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2023 | 12:31 pm

SPY

The Consumer Price Index (CPI) for the month of August has met the estimated value of 0.6%.

Portfolio Pulse from Bill Haddad

September 13, 2023 | 12:31 pm

SPY

The USA Core CPI (MoM) for August has increased to 0.3% against the estimated 0.2% and the prior value of 0.2%.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2023 | 12:30 pm

SPY

The Consumer Price Index (CPI) for August has come in at 3.7%, slightly above the estimated 3.6%.

Portfolio Pulse from Bill Haddad

September 13, 2023 | 12:30 pm

WKHS

Workhorse Group Inc. has received IRS approval as a qualified manufacturer for the Commercial Clean Vehicle Credit, which has led to a rise in its share prices.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2023 | 12:29 pm

SQFT

Trading of Presidio Property Trust shares has been halted due to pending news.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2023 | 12:26 pm

RCKT

Rocket Pharmaceuticals announced that it has reached alignment with the FDA on the global Phase 2 pivotal trial of RP-A501 for Danon Disease. This news has led to an increase in the company's share price.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2023 | 12:17 pm

OCGN

Ocugen has announced an update from its Phase 1/2 trial of OCU400, with 83% of subjects showing stabilization or improvement in the treated eye. The study also demonstrated a 'favorable safety and tolerability profile'.

Portfolio Pulse from Bill Haddad

September 13, 2023 | 12:17 pm